Diabetes has been incurable due to β-cell death and dysfunction in patients. β-cell preservation is thus emerging as a promising strategy to treat and reverse diabetes. A recent study by Dr. Wen-Chin Yang’s research group at the Research Center of Agricultural Biotechnology, identified Pdia4, a key regulator of β-cell failure, as a novel therapeutic target of diabetes. Pre-clinical studies of a Pdia4 inhibitor, PS1, were completed and PS1 is now ready for the application of investigational drug to FDA and clinical trials. This study has been published in EMBO Molecular Medicine on September, 2021.

Article Link: https://www.embopress.org/doi/full/10.15252/emmm.201911668